Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.34 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5029481 | 1.00 | EPHX1 (0.34) | EPHX1SMYD3L3MBTL1TRPM8BTK | |
| SCHEMBL16224000 | 0.77 | BTK (0.36) | EPHX1SMYD3BTK | |
| SCHEMBL16224001 | 0.77 | BTK (0.36) | EPHX1SMYD3BTK | |
| SCHEMBL5029182 | 0.74 | TRPV1 (0.34) | EPHX1TRPM8BTKKDM1APKM | |
| SCHEMBL19212856 | 0.74 | EPHX2 (0.34) | BTK | |
| SCHEMBL19212794 | 0.74 | EPHX2 (0.34) | BTK | |
| SCHEMBL19212816 | 0.74 | EPHX2 (0.34) | BTK | |
| SCHEMBL20679523 | 0.74 | EPHX2 (0.34) | BTK | |
| SCHEMBL28414512 | 0.74 | EPHX2 (0.34) | BTK | |
| SCHEMBL5033724 | 0.74 | GABRR1 (0.34) | SMYD3BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378409-B2 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCR2 | EPHX1 2141/4885SMYD3 3068/4885L3MBTL1 4606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.